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Muscle-specific RING finger protein 1 (MuRF1) is a sarcomere-
associated protein that is restricted to cardiac and skeletal muscle.
In skeletal muscle, MuRF1 is up-regulated by conditions that
provoke atrophy, but its function in the heart is not known. The
presence of a RING finger in MuRF1 raises the possibility that it is
a component of the ubiquitin–proteasome system of protein deg-
radation. We performed a yeast two-hybrid screen to search for
interaction partners of MuRF1 in the heart that might be targets of
its putative ubiquitin ligase activity. This screen identified troponin
I as a MuRF1 partner protein. MuRF1 and troponin I were found to
associate both in vitro and in vivo in cultured cardiomyocytes.
MuRF1 reduced steady-state troponin I levels when coexpressed in
COS-7 cells and increased degradation of endogenous troponin I
protein in cardiomyocytes. The degradation of troponin I in cardi-
omyocytes was associated with the accumulation of ubiquitylated
intermediates of troponin I and was proteasome-dependent. In
vitro, MuRF1 functioned as a ubiquitin ligase to catalyze ubiqui-
tylation of troponin I through a RING finger-dependent mecha-
nism. In isolated cardiomyocytes, MuRF1 reduced indices of con-
tractility. In cardiomyocytes, these processes may determine the
balance between hypertrophic and antihypertrophic signals and
the regulation of myocyte contractile responses in the setting of
heart failure.
cardiomyocyte
Cardiac hypertrophy is characterized by an enlargement of theheart associated with an increase in cardiomyocyte cell volume
and re-expression of certain fetal genes. Although cardiac hyper-
trophy is thought to benefit the heart initially by maintaining or
augmenting pump function, prolongation of the hypertrophic state
contributes to diastolic dysfunction and the development of ar-
rhythmias, sudden death, and heart failure (1). In contrast, the
reversal of hypertrophy is a powerful indicator of event-free sur-
vival in patients at otherwise high cardiovascular risk (2).
At the cellular level, cardiac hypertrophy is associated with
increased protein synthesis leading to addition of contractile myo-
fibers. It follows that the reversal of this process must include some
mechanism to delete unnecessary proteins, particularly sarcomeric
proteins that constitute the bulk of cardiomyocyte mass. In skeletal
muscle systems, where this process has been characterized most
carefully (3), atrophy, such as that induced by insulin deficiency,
accelerates degradation of muscle proteins by activation of protea-
some-dependent protein degradation along with the up-regulation
of mRNA levels of genes that encode distinct components of the
ubiquitin pathway (4). Although it was once commonly assumed
that the primary role of the ubiquitin-proteasome pathway is to
degrade abnormal and short-lived regulatory proteins (5, 6), studies
conducted by using proteasome inhibitors (7) and ATP depletion
(8, 9) indicate that this pathway also catalyzes the breakdown of
most long-lived proteins, such as myosin, actin, troponin, and
tropomyosin (3). However, the components of the ubiquitin-
proteasome system that regulate degradation of sarcomeric pro-
teins have remained elusive.
Recent screens for genes up-regulated in skeletal muscle atrophy
have identified two proteins restricted to skeletal and cardiac
muscle that may be components of the ubiquitin ligase family
(members of which represent the rate-limiting enzymes for addition
of polyubiquitin chains to proteins that are subsequently targeted to
the proteasome for ATP-dependent degradation). MAFbx
atrogin-1 is an F-box-containing protein that binds to Skp1cullin
complexes (10) and induces atrophy in skeletal myotubes (11).
Muscle-specific RING finger protein 1 (MuRF1) is one of a family
of three MuRFs that contain a tripartite RING:B-box:coiled-coil
domain, and deletion of MuRF1 in mice inhibits skeletal muscle
atrophy (12). RING finger-containing proteins are the largest
subset of ubiquitin ligases, although all proteins with RING fingers
are not ubiquitin ligases. A number of questions remain unanswered
about these proteins: What are the natural substrates for the
ubiquitin ligase activities of atrogin-1 and MuRF1? Is there func-
tional redundancy among MuRF1 family members? What are the
roles of these proteins in cardiac muscle?
MuRF1 interacts with the myofibrillar giant spring protein titin
at the M line (13, 14), resulting in disruption of the subdomain that
binds MuRF1. This interaction suggests that MuRF1 regulates the
stability of this large structural protein, although the functional
consequences of this interaction remain to be explored, and titin
does not appear to be a substrate for the ubiquitin ligase activity of
MuRF1. We have therefore searched for additional MuRF1 inter-
action partners as a means of understanding how its ubiquitin ligase
activity affects cardiomyocyte function.
Methods
Cell Culture and Transfection. COS-7 cells were transiently trans-
fected by using FuGene (Roche). Neonatal rat ventricular myocytes
(NRVM) were cultured in minimum essential medium containing
Earle’s salt with glutamine and 10% horse serum and 5% FBS.
Recombinant adenoviruses were constructed with the Ad-Easy
system, and cultures were infected for 24–48 h at a multiplicity of
infection (moi) of 1–20 as indicated. The expression of proteins in
the cells was routinely monitored by visualization of GFP fluores-
cence. In some experiments, adenovirus-infected cells were incu-
bated with 40 M MG132 or vehicle for 6 h before harvesting.
Expression Constructs. All control plasmids, GAL4 DNA-BD bait
vector (pGBKT7), and GAL4 AD prey vector (pACT2) used in the
two-hybrid screen were from the Matchmaker two-hybrid system 3
(BD Biosciences). The C terminus (143–351) of MuRF1 was cloned
in pGBKT7 (pGBKT7-CMuRF1). Adenovirus plasmids Ad.GFP,
Ad.GFP-CHIP, and Ad.GFP-Myc-MuRF1 (expressing GFP and
Myc-tagged MuRF1 bicistronically) were constructed in
pADTrack-CMV. Full-length mouse MuRF1 was cloned in vectors
pGEX-4AT-3 (GST-MuRF1), pGBKT7 (pGBKT7-MuRF1), and
Myc-pCMV (Myc-MuRF1). The RING finger domain (amino
acids 39–48) of the MuRF1 was deleted by PCR to obtain GST-
MuRFRF. Plasmid hemagglutinin (HA)-troponin I was con-
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structed by attaching an HA tag to the N terminus of troponin I by
PCR and cloning it into pcDNA3. GST-p68RacGAP was described
in ref. 15.
Yeast Two-Hybrid Screen. An activating domain fusion protein
human heart library (catalog no. HL4042AH, Clontech) cloned
into pACT2 (Marker: LEU2) was screened with pGBKT7-
CMuRF1. After nutritional selection, candidate clones were res-
cued on medium-stringency medium (SD-HisLeuTripX--gal)
and screened on high-stringency medium (SD-LeuTripHisAde
X--gal) to eliminate false positives.
Pulse–Chase Experiments. NRVM were infected with Ad.GFP and
Ad.GFP-Myc-MuRF1 at 0–20 moi for 8 h. Cells were labeled 48 h
later with [35S]methionine and cysteine [100 Ciml (1 Ci  37
GBq)] for 45 min, washed, and chased for 0, 4, 8, 12, 16, and 24 h.
Troponin I immunoprecipitates were separated by SDSPAGE,
and dried gels were autoradiographed.
In Vitro Ubiquitylation Reactions. In vitro ubiquitylation was per-
formed as described in ref. 16. In brief, bacterially expressed GST,
GST-Myc-MuRF1, or GST-MuRF1RF, 0.1 M purified rabbit
E1 (Calbiochem), 2.5 mgml ubiquitin (Sigma), and 1.6 M
UBCH5C were incubated in 20 mM Mops, pH 7.2100 mM KCl5
mM MgCl25 mM ATP10 mM DTT1 mM phenylmethylsulfonyl
fluoride for 4 h at 30°C. Samples were analyzed by SDSPAGE and
immunoblotting.
Indirect Immunofluorescence Microscopy. Primary cultures of
NRVM were treated with or without phenylephrine (PE) for 48 h,
followed by infection with Ad.GFP or Ad.GFP-Myc-MuRF1 for
24 h. Cells were fixed in 3.7% formaldehyde-PBS for 10 min and
permeabilized in 0.5% Triton X-100 and 1% BSA in PBS for 10
min. Cells were then incubated with mouse anti-troponin I (1:500)
or rabbit anti-Myc (1:200) for 90 min, followed by incubation with
anti-mouse Alexa 568 red (1:800) and anti-rabbit cascade blue
conjugated (1:500) for 45 min.
Contractility Measurements. NRVM infected with Ad.GFP or
Ad.GFP-Myc-MuRF1 for 48 h (moi 5) were field-stimulated at
a frequency of 0.5 Hz for a pulse duration of 5 ms at a sampling
rate of 240 Hz. Shortening was measured as movement of
high-contrast, 5-m microspheres (SPI Supplies, West Chester,
PA) that were attached to the cell surface. Motion of the
high-contrast edge along a selected rastor line segment was
enhanced and processed with a video edge-detection system
(Crescent Electronics, Sandy, UT) (17). Calibrated movement of
the microsphere was converted from analog to digital online. For
each cell, three consecutive field-stimulated contractions were
averaged. Contractile parameters measured were micrometer of
cell shortening, micrometer per millisecond cell shortening, and
micrometer per millisecond cell relengthening. The rate con-
stant of relengthening was calculated by normalizing the rate of
relengthening by the amount of cell shortening (Ad.GFP cells,
n  14; Ad.GFP-Myc-MuRF1 cells, n  15). Results are
representative of three independent experiments.
Results
MuRF1 Interacts with the Sarcomeric Protein Troponin I. Titin, a
megadalton-sized protein, has been shown to interact with a
144-residue segment of MuRF1 that contains the B-box and
surrounding sequences of MuRF1 (13). We sought to ascertain
whether other proteins bind to MuRF1 and to determine whether
any of these proteins are substrates for its putative ubiquitin ligase
activity. We performed a yeast two-hybrid screen by using residues
143–351 as a bait to screen an adult heart cDNA library. This region
contains highly conserved coiled-coil domains that are similar to
coiled-coil domains in sarcomeric proteins such as tropomyosin and
myosin (13), which suggested to us that this region may play a
regulatory role in sarcomere function. A total of 24 interacting
clones were identified out of 2.4  106 screened clones. Four of the
22 clones could be confirmed by high-stringency screening and
these encoded myosin-binding protein C (data not shown) and
troponin I. We performed two-hybrid wheel assays to test the
specificity of the interaction between MuRF1 and troponin I. By
using either high-stringency nutritional selection (Fig. 1A) or LacZ
expression (Fig. 1B), we found the interaction between MuRF1 and
troponin I to be both potent (relative to the interaction of p53 with
large T antigen) and highly selective.
We next examined whether MuRF1 associates in vivo with
endogenous troponin I in cardiomyocytes. In these experiments, we
also tested associations with related (ubiquitin ligase CHIP) and
unrelated (p68RacGAP) proteins to exclude fortuitous interaction.
Immunoblot analysis of NRVM lysates after adenoviral infection
confirmed the presence of MuRF1, GFP, CHIP, and troponin I
proteins (Fig. 1C), and microscopic analysis of GFP expression
indicated 95% infection rates in all conditions. The association
between MuRF1 and troponin I was tested by immunoprecipitating
troponin I (Fig. 1D) and MuRF1 (Fig. 1E) from NRVM infected
with Ad.GFP, Ad.GFP-Myc-MuRF1, or Ad.GFP-CHIP and mea-
suring the levels of MuRF1 and endogenous troponin I in immu-
nopellets. We found that troponin I and MuRF1 were indeed
components of the immunocomplex precipitated by either troponin
I or Myc (to detect MuRF1) Abs from lysate infected with
Ad.GFP-Myc-MuRF1. Neither troponin I nor MuRF1 could be
detected in immunopellets infected with control adenoviruses
(Ad.GFP and Ad.GFP-CHIP).
To further confirm the interaction between MuRF1 and tropo-
nin I, we performed GST pull-down assays. Glutathione beads
bound to fusion proteins GST-Myc-MuRF1 or controls (GST,
GST-CHIP, or GST-p68RacGAP) were incubated with NRVM
lysates. The presence of MuRF1 and troponin I complexes on
glutathione-agarose beads was tested by immunoblot analysis of
precipitated pellets with anti-Myc (to detect MuRF1) and anti-
troponin I Abs. Troponin I was pulled down by GST-Myc-MuRF1
but not by control beads (Fig. 1F). Finally, we mapped the domains
within MuRF1 that are responsible for interactions with troponin
I by using GST pull-down assays and mapped the interaction
domain to the first coiled-coil region located between amino acids
143 and 178 in MuRF1 (Fig. 1 G and H). These data confirm our
observations by using the yeast two-hybrid system and indicate that
MuRF1 interacts specifically with troponin I in vivo as well as in
vitro.
MuRF1 Colocalizes with Troponin I in Cardiac Myocytes. Previous
studies have shown that MuRF1 is found in several niches within
myocytes: the cytosol, nucleus, and along myofibrils (13, 18). We
also observed similar localization of MuRF1 in cardiomyocytes
treated with or without PE (Fig. 2, blue channel). Troponin I is
mostly bound to the contractile apparatus in the myocardium along
myofilaments, and 8% is found freely in the cytoplasm (19, 20).
We observed that troponin I is located in a striated pattern
throughout the breadth and length of NVRM untreated with PE
(Fig. 2, red channel). In the absence of PE treatment, there was
appreciable colocalization of MuRF1 and troponin I in NVRM,
although not all foci of troponin I expression along the sarcomere
contained dense foci of MuRF1 expression, which is consistent with
previous reports that MuRF1 is concentrated at distinct sites that
vary among individual sarcomeres (13). In NRVM treated with PE,
cells were larger, and both MuRF1 and troponin I were colocalized
along the myofibrils. In addition, after PE treatment both the
proteins were present in globule-shaped structures that were
present along the myofibrils and in the perinuclear region. Similar
localization patterns were observed in NRVM treated with endo-
thelin-1 and angiotensin II (data not shown). Given the results of
our subsequent experiments, it is tempting to speculate that these
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globules may represent domains primed for protein degradation
within cardiomyocytes.
MuRF1 Decreases Steady-State Levels of Troponin I by Increasing Its
Degradation. Based on the unusual colocalization pattern of
MuRF1 and troponin I and the putative ubiquitin ligase activity of
MuRF1, we next addressed whether increasing levels of MuRF1
would affect the stability of troponin I. To this end, we first
monitored troponin I protein levels by Western blotting by using
COS-7 cells cotransfected with plasmids expressing MuRF1 and
troponin I. The transfection of MuRF1 together with troponin I
Fig. 1. MuRF1 interacts with cardiac troponin I in vivo and in vitro. (A and B)
Troponin I was retrieved as one of the potential binding partners for MuRF1
in a two-hybrid screen. To reconfirm this binding, a wheel assay was per-
formed by using medium-stringency -gal filter assays (A) and high-stringency
X--gal in-gel assays (B). (C–E) To confirm the above interaction in vivo, NRVM
were infected with or without Ad.GFP, Ad.GFP-Myc-MuRF1, or Ad.GFP-CHIP at
2 moi. (C) After 24 h, cells were lysed and whole-cell lysates (WCL) were
immunoblotted (WB) with anti-Myc (to detect MuRF1), anti-GFP, anti-CHIP,
anti-troponin I, or anti-GAPDH as indicated. The cell lysates were immuno-
precipitated with anti-troponin I (D) or anti-Myc (E) Abs followed by Western
blotting with anti-Myc or anti-troponin I Abs. (F) To confirm the specificity of
the interaction between MuRF1 and troponin I, GST-fusion proteins GST-Myc-
MuRF1 and negative controls (GST alone, GST-CHIP, and GST-p68RacGAP)
were incubated with NVRM lysates that express endogenous troponin I. The
protein complexes were subjected to SDSPAGE and immunoblotted with
anti-Myc or anti-troponin I. (G) The region of MuRF1 involved in binding to
troponin I was analyzed in pull-down assays. (Upper) GST-MuRF1 fusion
proteins were analyzed by blotting with GST Ab . (Lower) The ability of the
various MuRF1 fusion proteins to bind to HA-tagged troponin I was analyzed
by blotting with HA Ab. (H) Schematic representations of MuRF1 residues that
bind to troponin I are indicated. RING, RING domain; MFC, MuRF family
conserved region; B-box, B-box domain domain; CC, coiled-coil domains; AR,
acidic region.
Fig. 2. MuRF1 colocalizes with troponin I in cultured cardiac myocytes.
Primary cultures of NVRM were treated with or without PE (100 M) for 48 h
followed by incubation with Ad.GFP-Myc-MuRF1. After fixing the cells in
formaldehyde, immunostaining was performed. Blue and red colors represent
MuRF1 and troponin I, respectively.











markedly decreased the expression of troponin I compared with
COS-7 cells expressing troponin I alone (Fig. 3A).
Although transient transfection experiments are informative,
they do not always accurately reflect the steady-state association of
two proteins in cells that constitutively express these proteins.
Therefore, we next asked whether endogenous troponin I levels are
affected by MuRF1 protein levels in NRVM treated with or without
PE. For this purpose, we infected NRVM with Ad.GFP or Ad.GFP-
Myc-MuRF1 at increasing titers and incubated the cells for 48 h
after the onset of GFP expression. Under these conditions, an moi
of between 1 and 5 results in near 100% infection efficiency for
NRVM. In Ad.GFP-infected NRVM, the steady-state levels of
troponin I were not appreciably altered, whereas the levels of
troponin I declined progressively with increasing titers of MuRF1
adenovirus (Fig. 3B). Troponin I levels were 4-fold higher after PE
treatment, and its stability was increased, whereas endogenous
MuRF1 protein levels did not decrease (data not shown), suggest-
ing that increased protein synthesis, adrenergic signaling, andor
sarcomere assembly may partially (but not completely) protect
troponin I from destabilization.
To quantify the down-regulation of troponin I, we examined
whether the overexpression MuRF1 reduces the half-life of endog-
enous troponin I by pulse–chase analysis of [35S]methionine plus
cysteine-labeled NRVM. The half-life of troponin I in NRVM in
the absence of PE stimulation was reduced from 17 h to 4 h after
adenoviral expression of MuRF1 (Fig. 3C). Troponin I protein
produced by NRVM treated with PE had a comparatively pro-
longed half-life, but increased MuRF1 levels similarly destabilized
troponin I under these conditions. Finally, we tested the specificity
of the effects of MuRF1 by examining its effects on other sar-
comere-associated proteins. Among the proteins tested, we found
that MuRF1 also decreased steady-state levels of troponin C and
myosin light chain-2 (Fig. 3D). Taken together, these results indi-
cate that MuRF1 down-regulates steady-state levels of troponin I by
increasing its degradation in cardiomyocytes and may have similar
activities on a select group of other contractile proteins as well.
MuRF1 Is a RING Finger-Dependent Ubiquitin Ligase That Targets
Troponin I for Proteasome-Dependent Degradation. Previous studies
have suggested that MuRF1 has ubiquitin ligase activity, but
definitive linkage of MuRF1 with ubiquitin-dependent degradation
via the proteasome is lacking because substrates for such an activity
have not been identified (11, 12). Based on our observations that
MuRF1 specifically binds to and decreases the half-life of troponin
I, we asked whether expression of MuRF1 mediates ubiquitylation
of endogenous proteins. To this end, we infected NRVM with
Ad.GFP-Myc-MuRF1 or Ad.GFP in the absence or presence of
MG-132, a selective inhibitor of proteasome activity. A slowly
migrating smear of high-molecular-weight proteins detectable by
immunoblot analysis for ubiquitin was enhanced in cells infected
with Ad.GFP-Myc-MuRF1, and the accumulation of these species
was accentuated in the presence of the proteasome inhibitor (Fig.
4A), indicating that MuRF1 enhances the ubiquitylation of endog-
enous proteins, consistent with a ubiquitin ligase activity. The same
lysates were also probed for the detection of troponin I, and the
level of troponin I was markedly reduced by MuRF1. The protea-
some inhibitor MG132 increased troponin I levels by 55% in
NRVM infected with Ad.GFP and by 210% in cells infected with
Ad.GFP-Myc-MuRF1, compared with untreated cells (Fig. 4A).
To test the effects of MuRF1 on troponin I ubiquitylation with
more sensitivity, we performed immunoprecipitations on NRVM
lysates with a troponin I-specific Ab, followed by Western blotting
with Abs specific for ubiquitin (to detect ubiquitylated species of
troponin I). These experiments indicated that MuRF1 increases
troponin I ubiquitylation, as detected by the accumulation of slowly
migrating ubiquitin immunoreactivity in troponin I immunopre-
cipitates that was further augmented by MG132 treatment (Fig.
4B). Blotting of troponin I in these immunoprecipitates indicated
that troponin I levels were decreased by MuRF1, and that these
levels were rescued by MG132 treatment. These experiments
indicate that MuRF1 serves as a ubiquitylation factor for endoge-
nous proteins in cardiomyocytes, one of which is troponin I.
Fig. 3. MuRF1 decreases troponin I protein expression by increasing its
degradation. (A) COS-7 cells were cotransfected with plasmids and lysed 48 h
later, and proteins from cell lysates were probed with Abs against Myc (to
detect MuRF1), troponin I, and GAPDH. (B) NRVM were treated with or
without PE for 48 h and then infected with Ad.GFP or Ad.GFP-Myc-MuRF1 at
0–20 moi for 8 h. Cell lysates were harvested 48 h after expression of GFP
fluorescence in cells. Proteins in the lysates were separated by SDSPAGE, and
Western blotting (WB) was performed with Abs against troponin I, Myc, and
GAPDH. (C) NRVM were treated with or without PE for 48 h, and they were
infected with adenovirus for 8 h. After washing, cells were pulse-labeled with
[35S]methionine and cysteine for 1 h and then chased for the indicated times.
Troponin I protein was immunoprecipitated and separated by SDSPAGE.
Quantification of results are plotted as the percentage of troponin I protein
at the 0-h value (in log scale) against time. A representative of three inde-
pendent experiments is shown. (D) Western blot analysis of proteins from
NRVM treated with the indicated adenoviruses. -MHC, -myosin heavy chain;
MLC2, ventricular myosin light chain-2; CaActin, cardiac actin.
18138  www.pnas.orgcgidoi10.1073pnas.0404341102 Kedar et al.
Moreover, MuRF1 is a rate-limiting factor for these ubiquitylation
events.
In vitro ubiquitylation assays were performed with recombinant
proteins to directly test the ubiquitin ligase activity of MuRF1. We
used an approach similar to that used to characterize the ubiquitin
ligase activity of the RING finger protein c-Cbl, in which ubiqui-
tylation in the absence of a specific substrate is tested as an
indication of multiubiquitin chain assembly that occurs either
freely, on co-purifying proteins, or on the ubiquitin ligase itself (21).
Bacterially expressed MuRF1 (as a GST fusion) and UBCH5c, an
E2 ubiquitin-conjugating enzyme, were incubated in a reaction
containing ubiquitin, E1 and troponin I, and these reaction mixtures
were probed simultaneously by Western blotting with an anti-
ubiquitin or anti-troponin I Ab. Ubiquitylation activities, as as-
sessed by the detection of high-molecular-weight multiubiquitin
chains of ubiquitin and ubiquitylated troponin I, were detected only
in reactions containing E1, UBCH5c, and MuRF1 in the presence
of ubiquitin (Fig. 4C). Deletion of any single component in this
reaction abolished troponin I ubiquitylation.
MuRF1 contains an amino-terminal RING finger, and the family
of RING finger proteins is linked with ubiquitin ligase activity in
many cases. If the ability of MuRF1 to down-regulate troponin I is
truly due to ubiquitin ligase activity, then disruption of the RING
finger domain should abrogate its ubiquitin ligase activity. To test
this hypothesis, we deleted the RING finger and examined the
ubiquitin ligase activity of this mutant in the reconstituted ubiqui-
tylation assay. Deletion of the RING finger totally abolished
ubiquitylation of troponin I (Fig. 4C). Taken together, our data
indicate that MuRF1 is the ubiquitin ligase responsible for cata-
lyzing proteasome-dependent degradation of troponin I and that
the RING finger domain of MuRF1 is required for its ubiquitin
ligase activity.
Effects of MuRF1 on Cardiomyocyte Contractility. We examined
contractility in neonatal cardiomyocytes to test the effects of
MuRF1 on sarcomere function. Cell shortening and rate of short-
ening during field-stimulated contractions were measured in iso-
lated cardiomyocytes infected with Ad.GFP or Ad.GFP-Myc-
MuRF1 for 48 h. Increasing MuRF1 levels in cardiomyocytes
decreased both maximal shortening and the rate of shortening
(dLdt) by 25%. In contrast, the relaxation rate constant (rate of
relaxation normalized to total shortening) was unchanged by
MuRF1. In addition, we noted that MuRF1 dose-dependently
decreased the frequency of spontaneous cardiomyocyte contrac-
tions by 70% at an moi of 1 without affecting viability. Although we
do not know whether these effects are entirely dependent on the
ubiquitin ligase activity of MuRF1, these observations indicate that
MuRF1 impairs both contractile responses and beating frequencies
in NRVM, which underscores the functional consequences of
MuRF1-dependent perturbations in the sarcomere.
Discussion
MuRF1 was originally identified by searching for genes up-
regulated in models of skeletal muscle atrophy (11). The restriction
of its expression to skeletal and cardiac muscle suggests that it may
be part of the general program to regulate cell size in myocytes. To
explore this possibility, and to identify potential targets for the
ubiquitin ligase activity of MuRF1, we performed a yeast two-
hybrid screen that identified troponin I as a MuRF1 interaction
partner. In this report, we demonstrate that MuRF1–troponin I
interactions can be detected in cardiomyocytes. MuRF1 decreases
steady-state levels of troponin I by inducing its ubiquitylation and
proteasome-dependent degradation. By using in vitro reconstitution
assays, we show that MuRF1 is a bona fide RING finger-dependent
ubiquitin ligase that catalyzes a rate-limiting step in troponin I
degradation. Although degradation of troponin I via the protea-
some has previously been described, the identity of the protein(s)
responsible has until now been elusive.
Interaction of titin with MuRF1 in sarcomeres has previously
been reported (13, 18). Our data and that of other groups indicate
that MuRF1 exists in multiple locations within the cell, including
the cytosol, along the sarcomere, and within the nucleus. In the
cytosol, MuRF1 is the only MuRF family member that binds to titin
(13). The present studies extend the list of sarcomeric proteins that
bind MuRF1 to include troponin I. It is important to note that
MuRF1 does not appear to target titin for degradation (13),
whereas for troponin I it does. Interestingly, in cardiomyocytes
treated with PE, both MuRF1 and troponin I colocalize along
myofibrils and are also present in small globule-shaped structures
along the myofibrils and in the perinuclear region (Fig. 2). It is
tempting to speculate that these globules may represent domains of
ubiquitin-dependent protein degradation within cardiomyocytes
that are analogous to so-called aggresomes (22, 23). These globules
may serve as nucleation sites for the degradation of sarcomeric
proteins by ubiquitin ligases such as MuRF1 when rates of protein
turnover are high.
Fig. 4. MuRF1 induces ubiquitylation of troponin I in vivo and in vitro. (A)
NRVM were infected with Ad.GFP or Ad.GFP-Myc-MuRF1 and treated with
MG-132 for 6 h. Ubiquitin (Ub) conjugates from lysates were separated by
SDSPAGE, and Western blotting (WB) was performed with an anti-ubiquitin
Ab. Cell lysates were blotted simultaneously with anti-troponin I, anti-Myc,
anti-GFP, and anti-GAPDH. NS, nonspecific; MW, molecular weight. (B and C)
Lysates were subjected to immunoprecipitation with anti-troponin I followed
by immunoblotting with anti-ubiquitin (B) or were directly probed with
anti-troponin I (C) Abs to detect ubiquitylated species of troponin I. (D) In vitro
ubiquitylation reactions were performed to test the ubiquitin ligase activity of
MuRF1. Ubiquitin conjugates of troponin I were detected with anti-ubiquitin
(Upper) and anti-troponin I (Lower) Abs. The ubiquitylation of troponin I is
noticeable as the accumulation of slower-migrating species of troponin I with
concomitant loss of the ubiquitylated protein.











Protein degradation in striated muscle proceeds via three pro-
teolytic systems. Lysosomal proteases are responsible for degrada-
tion of endocytosed proteins including membrane proteins (24–26).
The cytosolic proteases -calpain and m-calpain trigger proteolytic
cleavage of target proteins (frequently in response to phosphory-
lation events) (27); calpain-dependent cleavage may either clear the
target protein or, on occasion, lead to the generation of stable
proteolytic intermediates with gain-of-function activity. The ubiq-
uitin-proteasome system is a major ATP-dependent pathway for
protein degradation in muscle, particularly for myofibrillar proteins
that comprise the majority of muscle proteins. In skeletal muscle,
the rapid degradation of muscle proteins in response to fasting,
disuse, or aging takes place because of activation of ubiquitin-
proteosome pathways (11, 12). Much more is known about path-
ways of protein degradation in skeletal muscle than in cardiomy-
ocytes, although it is generally assumed that the processes are
similar.
Troponin I undergoes degradation via two mechanisms. Tro-
ponin I is proteolytically cleaved by calpains after ischemia-
reperfusion injury. This generates a 193-aa cleavage product that
accumulates in the stunned myocardium (28–31). Overexpres-
sion of this troponin I fragment causes cardiac dysfunction in
mice (32), indicating that calpain-dependent proteolysis of tro-
ponin I leads to a toxic gain-of-function intermediate. In addi-
tion, purified troponins (as well as myosin, actin, and tropomy-
osin) are readily degraded via the ubiquitin-proteasome pathway
in muscle extracts (3). Our data indicate that MuRF1 is a key
component of the ubiquitin ligase complex that is required for
troponin I ubiquitylation and degradation, whereas we do not
see the typical cleavage products of troponin I that are induced
by calpains; in other words, MuRF1-dependent ubiquitylation
and calpain-dependent proteolysis appear to be distinct cellular
processes. The ability of MuRF1 to induce complete proteolysis
of troponin I bypasses the possibility of accumulation of the types
of toxic proteolytic intermediates that appear after calpain-
dependent cleavage, thus providing a biological rationale for the
existence of two independent proteolytic mechanisms for tro-
ponin I degradation.
Interestingly, troponins are resistant to degradation by the ubiq-
uitin-proteasome pathway when present in myofibrils or in soluble
actomyosin complexes (3). This observation indicates that specific
linkages in the contractile apparatus protect troponins from ubiq-
uitylation and suggests that the dissociation of free myosin, tropo-
nin, and other myofibrillar proteins from contractile filaments is the
rate-limiting step in their degradation. These observations may be
relevant to the role played by MuRF1 in the sarcomere. MuRF1
binds to titin and disrupts its interactions with the M-line without
inducing the degradation of titin, thus partially disrupting sarco-
mere assembly (18). We hypothesize that MuRF1 may destabilize
sarcomeres by binding to titin, which would in turn provide MuRF1
with access to its substrate troponin I. Troponin I could then be
targeted for ubiquitylation and proteasome-dependent degradation
by MuRF1. This activity of MuRF1 may be generalized to other
sarcomere accessory proteins (Fig. 3D).
Functionally, we found that MuRF1 reduces cardiomyocyte
contractility and beating frequencies. These effects most likely
reflect the summation of the effects of MuRF1 on sarcomeric
proteins, which emphasizes the need to characterize the full range
of substrates that are recognized for degradation by MuRF1.
Nevertheless, the effects of MuRF1 on contractility are consistent
with the reported effects of loss of troponin I function. Deletion of
troponin I results in decreased contractility and cardiac dysfunction
in mice (33), and a recessive mutation in troponin I that disrupts
assembly of the troponin complex also results in a contractility
defect in humans (34). It is tempting to speculate that disassembly
of sarcomeres by molecules such as MuRF1 may be a maladaptive
response that contributes to wall thinning and contractile dysfunc-
tion in dilated cardiomyopathies.
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